▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #872 by analyst upside · 2026-09-27
NTLA
Intellia Therapeutics, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+104.3%
implied upside to consensus target
Current Price $11.75
Consensus Target $24.0
Bull Target $61.0
Bear Target $8.0
Analysts Covering 17
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
8
Hold
5
Sell
3
52-Week Low $7.95
52-Week High $28.25
YTD Return +27.6%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.34
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $60M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $7.95
52-Week High $28.25
Current Price $11.75
Bear Target $8.0
Bull Target $61.0
● Now $11.75 ● Target $24.0
TRADING DATA
Avg Volume 3.9M
YTD Return +27.6%
Analyst Count 17
Consensus Hold
Upside to Target +104.3%
Last Updated 2026-09-27

ANALYST SUMMARY

Intellia Therapeutics, Inc. (NTLA) is currently trading at $11.75 with a Wall Street consensus price target of $24.0, implying potential upside of 104.3% over the next 12 months. 17 analysts currently cover NTLA, with a consensus rating of Hold - 53% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $61.0, while the most cautious has a target of $8.0.

NTLA operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 27.6% year-to-date and is currently trading near the lower end of its 52-week range of $7.95 – $28.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GTBIF +106.5%
Green Thumb Industries Inc.
$2B · P/E 14.4x · Buy
INVA +68.8%
Innoviva, Inc.
$1B · P/E 4.8x · Buy
ADMA +81.2%
ADMA Biologics, Inc.
$2B · P/E 13.4x · Buy
VOR +110.6%
Vor Biopharma Inc.
$1B · P/E 0.1x · Buy
ANIP +42.9%
ANI Pharmaceuticals, Inc.
$2B · P/E 16.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for NTLA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens reit
Market Outperform → Market Outperform 2026-09-09 Building track record
Wedbush - Reiterated
Neutral → Neutral 2026-09-09 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-09-09 31% win rate (48 calls)
Citizens reit
Market Outperform → Market Outperform 2026-08-25 Building track record
Evercore ISI Group ↑ Upgrade
In-Line → Outperform 2026-08-07 Building track record
Wolfe Research ↓ Downgrade
Peer Perform → Underperform 2026-07-16 Building track record
Wedbush - Reiterated
Neutral → Neutral 2026-07-10 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-06-16 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
29
out of 100
Coverage depth
22/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →